Cardinal Health (NYSE:CAH - Get Free Report) had its price objective hoisted by Robert W. Baird from $197.00 to $203.00 in a research note issued to investors on Wednesday,Benzinga reports. The brokerage currently has an "outperform" rating on the stock. Robert W. Baird's target price suggests a potential upside of 38.56% from the company's current price.
A number of other equities research analysts have also recently issued reports on the company. Citigroup restated a "neutral" rating and issued a $170.00 price objective (up from $157.00) on shares of Cardinal Health in a research note on Friday, June 13th. Leerink Partners set a $186.00 price objective on Cardinal Health and gave the company an "outperform" rating in a research note on Tuesday. Wells Fargo & Company restated an "overweight" rating on shares of Cardinal Health in a research note on Wednesday. Evercore ISI restated an "outperform" rating and issued a $180.00 price objective (up from $175.00) on shares of Cardinal Health in a research note on Thursday, June 12th. Finally, Wall Street Zen lowered Cardinal Health from a "strong-buy" rating to a "buy" rating in a report on Saturday, August 2nd. Three equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company's stock. Based on data from MarketBeat, Cardinal Health presently has a consensus rating of "Moderate Buy" and an average target price of $162.13.
Get Our Latest Stock Report on CAH
Cardinal Health Price Performance
NYSE CAH opened at $146.51 on Wednesday. The stock has a market capitalization of $34.97 billion, a price-to-earnings ratio of 22.86, a PEG ratio of 1.57 and a beta of 0.67. Cardinal Health has a one year low of $100.80 and a one year high of $168.44. The business's fifty day moving average is $159.92 and its 200-day moving average is $144.18.
Cardinal Health (NYSE:CAH - Get Free Report) last announced its quarterly earnings data on Tuesday, August 12th. The company reported $2.08 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.03 by $0.05. Cardinal Health had a negative return on equity of 68.84% and a net margin of 0.70%. The business had revenue of $60.16 billion for the quarter, compared to analysts' expectations of $60.91 billion. During the same period in the previous year, the business posted $1.84 EPS. The firm's quarterly revenue was up .5% compared to the same quarter last year. Research analysts expect that Cardinal Health will post 7.95 EPS for the current fiscal year.
Institutional Inflows and Outflows
Institutional investors have recently modified their holdings of the stock. Greykasell Wealth Strategies Inc. purchased a new stake in Cardinal Health during the first quarter valued at about $26,000. Jones Financial Companies Lllp lifted its position in Cardinal Health by 198.3% in the first quarter. Jones Financial Companies Lllp now owns 21,112 shares of the company's stock valued at $27,000 after purchasing an additional 14,034 shares during the last quarter. Atlantic Edge Private Wealth Management LLC increased its holdings in Cardinal Health by 75.0% during the 2nd quarter. Atlantic Edge Private Wealth Management LLC now owns 175 shares of the company's stock valued at $29,000 after purchasing an additional 75 shares during the period. Bellwether Advisors LLC bought a new position in shares of Cardinal Health during the fourth quarter valued at approximately $32,000. Finally, Tompkins Financial Corp lifted its position in shares of Cardinal Health by 106.7% in the 1st quarter. Tompkins Financial Corp now owns 248 shares of the company's stock worth $34,000 after purchasing an additional 128 shares during the period. 87.17% of the stock is currently owned by institutional investors.
Cardinal Health Company Profile
(
Get Free Report)
Cardinal Health, Inc operates as a healthcare services and products company in the United States, Canada, Europe, Asia, and internationally. It provides customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices, and patients in the home.
Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Cardinal Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cardinal Health wasn't on the list.
While Cardinal Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.